MoS2-based fluorescence sensor for the detection of breast cancer-related microRNA

doi:10.3969/j.issn.1673-8640.2017.05.018

Abstract

Abstract:

Objective To establish a fast,convenient,sensitive and specific fluorescence sensor based on novel nanomaterial MoS₂ to detect breast cancer-related microRNA（miRNA）. Methodse The fluorescence sensor was fabricated by mixing novel nanomaterial MoS₂ with fluorescent dye-labeled DNA probe. Noncomplementary miRNA,one-base mismatched miRNA and different concentrations of complementary miRNA were introduced to fluorescence sensor for hybridization with DNA probe. The miRNA was detected through monitoring fluorescence signal change before and after DNA probe-miRNA hybridization. Results The pmol/L level of complementary miRNA could be detected within 40 min,and fluorescence sensor could discriminate complementary miRNA from noncomplementary miRNA and one-base mismatched miRNA. Conclusions The novel nanomaterial MoS₂-based fluorescence sensor has the advantages of fast,high sensitivity and specificity,and it is potential for the detection of breast cancer-related miRNA.

Key words: MoS2, Fluorescence sensor, Breast cancer, MicroRNA

CLC Number:

R446.1

CAI Bingjie, ZHANG Guojun, LI Yan. MoS₂-based fluorescence sensor for the detection of breast cancer-related microRNA[J]. Laboratory Medicine, 2017, 32(5): 427-430.

Figures/Tables 5

References 14

[1]	石建伟,唐智柳,蔡美玉,等. 2008~2012年我国女性乳腺癌流行状况的系统性综述[J]. 中国妇幼保健,2014,29(10):1622-1626.
[2]	魏旭倩,王伟祥,王学锋,等. 外周血CEA mRNA、Survivin mRNA、MMP-2 mRNA和TIMP-2 mRNA水平与乳腺癌的关系[J]. 检验医学,2011,26(2):94-99.
[3]	GAO J,ZHANG Q,XU J,et al.Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA[J]. Chin J Cancer Res,2013,25(6):743-748.
[4]	王卉,刘水逸,吴唐维,等. miR-21 在乳腺癌中的表达及其对乳腺癌侵袭转移的影响[J]. 中华检验医学杂志,2015,38(3):186-190.
[5]	PETROVIĆ N,MANDUŠIĆ V,STANOJEVIĆ B,et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion[J]. Med Oncol,2014,31(3):867.
[6]	KUMAR S,KEERTHANA R,PAZHANIMUTHU A,et al.Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients[J]. Indian J Biochem Biophys,2013,50(3):210-214.
[7]	LIU J,LU Y.A DNAzyme catalytic beacon sensor for paramagnetic Cu2+ ions in aqueous solution with high sensitivity and selectivity[J]. J Am Chem Soc,2007,129(32):9838-9839.
[8]	ZHU C,ZENG Z,LI H,et al.Single-layer MoS2-based nanoprobes for homogeneous detection of biomolecules[J]. J Am Chem Soc,2013,135(16):5998-6001.
[9]	RAFIEE-POUR H A,BEHPOUR M,KESHAVARZ M. A novel label-free electrochemical miRNA biosensor using methylene blue as redox indicator:application to breast cancer biomarker miRNA-21[J]. Biosens Bioelectron,2016,77:202-207.
[10]	CROCE C M.Causes and consequences of microRNA dysregulation in cancer[J]. Nat Rev Genet,2009,10(10):704-714.
[11]	BOERI M,VERRI C,CONTE D,et al.MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer[J]. Proc Natl Acad Sci U S A,2011,108(9):3713-3718.
[12]	IORIO M V,CROCE C M.MicroRNA dysregulation in cancer:diagnostics,monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med,2012,4(3):143-159.
[13]	GUO S,YANG F,ZHANG Y,et al.Amplified fluorescence sensing of miRNA by combination of graphene oxide with duplex-specific nuclease[J]. Anal Methods,2014,6(11):3598.
[14]	XI Q,ZHOU D M,KAN Y Y,et al.Highly sensitive and selective strategy for microRNA detection based on WS2 nanosheet mediated fluorescence quenching and duplex-specific nuclease signal amplification[J]. Anal Chem,2014,86(3):1361-1365.

核酸	序列（5'~3'）	碱基数
荧光标记DNA探针	TCAACATCAGTCTGATAAGCTA-FAM	22
miRNA-21序列	UAGCUUAUCAGACUGAUGUUGA	22
单碱基错配miRNA	UAGCUUAUCAGACUGAAGUUGA	22
非互补miRNA	AGAGGAUGUUAGUAAGGUGGUU	22

核酸	序列（5'~3'）	碱基数
荧光标记DNA探针	TCAACATCAGTCTGATAAGCTA-FAM	22
miRNA-21序列	UAGCUUAUCAGACUGAUGUUGA	22
单碱基错配miRNA	UAGCUUAUCAGACUGAAGUUGA	22
非互补miRNA	AGAGGAUGUUAGUAAGGUGGUU	22

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628.
[3]	PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration，invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646.
[4]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[5]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[6]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[7]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[8]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[9]	LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329.
[10]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[11]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[12]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[13]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[14]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[15]	ZHU Qian, ZHU Lifang, MA Caiyun, YAO Jie. Relation of serum miR-140-5p and PGC-1α mRNA expression with vascular cognitive impairment in acute ischemic stroke patients [J]. Laboratory Medicine, 2023, 38(11): 1069-1074.

MoS₂-based fluorescence sensor for the detection of breast cancer-related microRNA

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 14

Related Articles 15

Recommended Articles

Metrics